title: Molecular mapping the presence of druggable targets in preinvasive and precursor breast lesions: a comprehensive review of biomarkers related to therapeutic interventions.
abstract: The analysis of clinical breast samples using biomarkers is integral to current breast cancer management. Currently, a limited number of targeted therapies are standard of care in breast cancer treatment. However, these targeted therapies are only suitable for a subset of patients and resistance may occur. Strategies to prevent the occurrence of invasive lesions are required to reduce the morbidity and mortality associated with the development of cancer. In theory, application of targeted therapies to pre-invasive lesions will prevent their progression to invasive lesions with full malignant potential. The diagnostic challenge for pathologists is to make interpretative decisions on early detected pre-invasive lesions. Overall, only a small proportion of these pre-invasive lesions will progress to invasive carcinoma and morphological assessment is an imprecise and subjective means to differentiate histologically identical lesions with varying malignant potential. Therefore differential biomarker analysis in pre-invasive lesions may prevent overtreatment with surgery and provide a predictive indicator of response to therapy. There follows a review of established and emerging potential druggable targets in pre-invasive lesions and correlation with lesion morphology.
authors: Centre for Cancer Research and Cell Biology, Queen's University, Belfast BT9 7BL, UK. d.boyle@qub.ac.uk
authors: David P
authors: DP
authors: Boyle
authors: Paul
authors: P
authors: Mullan
authors: Manuel
authors: M
authors: Salto-Tellez
mesh_terms: D000951:Antigens, Neoplasm / Q000032:analysis / Q000502:physiology; D015415:Biomarkers; D001943:Breast Neoplasms / Q000737:chemistry* / Q000188:drug therapy; D004250:DNA Topoisomerases, Type II / Q000032:analysis / Q000502:physiology; D004268:DNA-Binding Proteins / Q000032:analysis / Q000502:physiology; D005260:Female; D006801:Humans; D051059:PTEN Phosphohydrolase / Q000032:analysis / Q000737:chemistry / Q000502:physiology; D019869:Phosphatidylinositol 3-Kinases / Q000032:analysis / Q000737:chemistry / Q000502:physiology; D011230:Precancerous Conditions / Q000737:chemistry*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis / Q000737:chemistry / Q000502:physiology; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D042461:Vascular Endothelial Growth Factor A / Q000737:chemistry / Q000502:physiology
chemical_list: D000951:Antigens, Neoplasm; D015415:Biomarkers; D004250:DNA Topoisomerases, Type II; D004268:DNA-Binding Proteins; D051059:PTEN Phosphohydrolase; D019869:Phosphatidylinositol 3-Kinases; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D042461:Vascular Endothelial Growth Factor A; C508053:ERBB2 protein, human